×

RNS Number : 3344T

MyHealthChecked PLC

24 November 2021

 

MyHealthChecked PLC 

("MyHealthChecked" or the "Company")

 

Launch of COVID-19 Day 2 rapid antigen test and verification service

 

MyHealthChecked Plc (AIM: MHC), announces the launch of two home testing services for travellers entering and departing the UK. On 24 November the company will begin selling a rapid antigen test and a verification service for residents and vaccinated travellers arriving in England from a non-red list country, followed by a Fit to Fly rapid test for travellers leaving the UK launching next week.

 

The online service will allow customers to order a test before arriving into England (where COVID-19 travel rules are different to those in Scotland, Wales and Northern Ireland) or departing from the UK. The test can be taken at home with results verified by a trained professional within 2 hours of completing the test. Customers are then notified by email when the result is ready, and a QR-code secured COVID-19 result certificate is made available for download.

 

The service will utilise the CE approved, ISO certified and UK Government validated FlowFlex® Rapid Test Kit, a lateral flow test that is easy to administer via a simple nasal swab, which provides results in 15 minutes and offers 98.8% accuracy.  

 

MyHealthChecked has also partnered with medical specialists Mediskills, who will provide fully trained NHS professionals to verify test results as part of this service. MyHealthChecked will have full responsibility for overseeing the service, processing orders and dispatches, as well as warehousing test kit stock. The Company will continue to maintain the high standards of customer service already being delivered across its other testing services.

 

MyHealthChecked remains a high-quality laboratory provider but has adapted to evolving market requirements, allowing the Company's reputation for delivering a good customer experience and a reliable testing service across a wider variety of testing formats.

 

Penny McCormick, Chief Executive Officer of MyHealthChecked PLC , commented: "I am delighted to announce the launch our new COVID-19 Day 2 rapid antigen testing service. Our agility in adapting to the changing market needs shows the strength of our team, our digital platform, and our ability to offer customers highly compliant testing services via on a digital platform that gives a great user experience. Our focus on ensuring the best possible customer service has already allowed us to meet the needs of our key retail partners and has established a trusted relationship based on the best possible service delivery."

 

MyHealthChecked PLC		www.myhealthchecked.com
P enny McCormick , Chief Executive Officer		via Walbrook PR
Gareth Davies, Chief Financial and Operations Officer
SPARK Advisory Partners Limited (NOMAD)		Tel: +44 (0)20 3368 3550
Neil Baldwin
Oberon Capital Ltd (Broker)		Tel: +44 (0)203 179 5344
Mike Seabrook		[email protected]
Walbrook PR Ltd (Media & IR)	Tel: +44 (0)20 7933 8780 or [email protected]
Paul McManus / Alice Woodings		Mob: +44(0)7980 541 893 / +44 (0)7407 804 654

 

 

About MyHealthChecked PLC   ( www.myhealthcheckedplc.com )

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests. MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests, now in development following the acquisition of The Genome Store in November 2020. The tests will be made available online and would be viable for over-the-counter purchase. 

The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market, with a focus on accessibility at the right price, led by UK-based experts.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCFLFLTLILVFIL

Close

×

RNS Number : 6068S

Silver Bullet Data Services Grp PLC

17 November 2021

 

17 November 2021

Silver Bullet Data Services Group plc

("Silverbullet" or the "Company", or, together with its subsidiaries, the "Group")

New Contract Win

 

Silverbullet, a provider of digital transformation services and products, is pleased to announce it has been awarded its first significant '4D' agency contract with pilot GmbH & Co.KG ("pilot"), one of the largest independent media agencies in Germany.

 

pilot is part of the Local Planet network with whom Silverbullet has a joint venture. pilot manages approximately €1.2bn of media billings annually, services more than 200 clients, and is recognised as one of the top 10 German media agencies according to the RECMA rankings.  This contract is part of the roll out of 4D across multiple geographies and languages, laying the foundation for further growth in 2022 as the use of third-party cookies continues to diminish within the advertising ecosystem.

 

4D is a next-generation contextual solution used to target and deliver deterministic insights for advertisers, driving 'in-the-moment' marketing and brand suitability for digital media buying. It addresses the fundamental desire of advertisers and their brands to be seen in the right moment and context that is most likely to drive engagement, whilst seeking to generate powerful business outcomes and increased revenues.

 

4D will be the preferred partner for pilot in contextual display and video for programmatic media campaigns. 4D will be offered across the pilot client portfolio for the generation of contextual customer insights and the planning of media deployment.

 

Ian James, Chief Executive Officer of Silverbullet, commented:

" We are delighted to be partnering with pilot and its broad client base on their journey through the 'post cookie' era. To have such a distinguished and scaled media organisation such as pilot to choose 4D to deliver this mission critical transformation from third-party cookies to contextual data is an excellent endorsement of our market leading product and strategy."

 

Uli Kramer co-founder of pilot, stated:

"As the 'post cookie' advertising era dawns, we are seeking reliable and scaleable platforms to help us target advertising in a data compliant and effective manner. 4D has proven to outperform for us in  'post cookie' insights and targeting, and I am excited about the future with 4D helping us to drive improved business outcomes for our clients."

 

For further information please contact:

 

Silverbullet
Ian James (CEO)	via IFC
Strand Hanson Limited – Financial and Nominated Adviser
James Spinney / James Bellman / James Dance	0207 409 3494
Oberon Capital – Broker	0203 179 5344
Mike Seabrook / Robert Hayward
IFC Advisory	020 3934 6630
Graham Herring / Tim Metcalfe / Florence Chandler	07793 839 024

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018.

About Silverbullet

Silverbullet's proprietary 4D advertising solution is designed to help advertisers target consumers in a "post cookie world". The product is a natural extension to its existing services business which already serves a blue-chip client base such as Heineken, Channel 4, Amazon, ITV and Jägermeister amongst many others.

 

The removal of cookies has already been implemented by web browsers such as Firefox and Safari, with Google expected to phase out the use of cookies in 2022. 

Headquartered in London, the Group employs 66 employees across five regions across the globe, including, the UK, Italy, Germany, Australia and the US. The Group continues to look at other opportunities for expansion worldwide.

The Company has an established and growing services business with significant accumulated industry experience and a proven track record of delivering strategic projects and activation services to its clients.

The majority of the Board have held senior positions at global software companies and have significant industry experience across data engineering, SAAS product development and marketing.

The Group has close technical and commercial partnerships with Salesforce, Oracle and Adobe, all of which have existing sales channels and are already delivering to clients.

The Group has established a joint venture and strategic partnership with Local Planet, a scaled network of over 60 agencies across the globe which transact, in aggregate, over US$16 billion of media buying on behalf of their clients. The Local Planet joint venture, established in December 2020, which has already generated material services revenues for the Group, presents a significant opportunity to provide further data services and the 4D product to the Local Planet agency network.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTFFFIFLALRLIL

Close

×

Neville Registrars is delighted to welcome Technology Minerals plc as the newest addition to its list of client companies.

Technology Minerals is a UK-based company looking to create a circular economy for battery metals within one group.

Further information can be found on the Company's website: https://www.technologyminerals.co.uk/

Close

×

RNS Number : 4520S

LoopUp Group PLC

16 November 2021

 

16 November 2021

LOOPUP GROUP PLC
("LoopUp" or the "Group")

 

Cloud Telephony contract wins

 

LoopUp Group plc (AIM: LOOP), the cloud platform for premium specialist communications, is pleased to announce eight additional direct customer contract wins in its Cloud Telephony business unit.

 

In Q3 2020, the Group announced the launch of its internationally differentiated Cloud Telephony solution, integrated into Microsoft Teams via 'Direct Routing' peering with Microsoft. This global capability enables customers to make phone calls to external phone numbers and receive phone calls to their own work phone numbers, all directly from their Microsoft Teams user interfaces.

 

The Group has now extended its number of new direct contract wins to 23 during 2021, an additional eight since our last update. These wins represent, in aggregate, total contract value ranging from a baseline minimum of £2.1 million for initially committed and contracted deployment phases (a 24% increase since our last update) to an expected c.£7.9 million should geographic rollouts proceed as expected (a 55% increase since our last update).

 

The geographic rollouts involved in most of these contract wins reflects LoopUp's target market for its Cloud Telephony solution: relatively large, relatively international enterprises. To date, all customer deployments have been successful, and all rollouts are progressing positively.

 

The Group's sales pipeline of direct Cloud Telephony opportunities has also continued to grow and mature. The total pipeline now stands at £63 million of potential Annual Contract Value (ACV), of which approximately 20% is at later stages of the sales cycle (written proposal or later).

 

The Group's new Cloud Telephony contract wins and pipeline growth reflect its differentiated value proposition to relatively large, relatively international enterprises, enabling them to work with one vendor partner globally rather than multiple geographic-specific carriers. Specifically, this differentiation includes:

 

· Market-leading geographic coverage – regulated and compliant platform service provision in approximately 80 countries by H1 2022, and platform integrations with 19 carefully selected tier-1 carrier partners for highest quality voice routing;

· Deep, multilingual Microsoft voice expertise – recently awarded the 'Calling for Microsoft Teams Advanced Specialization' by Microsoft, which represents the highest competency tier (above Microsoft's gold level) for customer solution configuration and implementation;

· Global Administration Portal – a customer software portal for enterprise customers, enabling visibility and management of phone numbers, users and usage/spend analysis on a global level; and

· 'PerfectBundleTM' pricing -enables multinational customers to pool their committed spend across their international billing entities.

 

 

For further information, please contact:

 

LoopUp Group plc	via FTI
Steve Flavell, co-CEO
Panmure Gordon (UK) Limited	+44 (0) 20 7886 2500
Dominic Morley / Alina Vaskina (Corporate Finance)
Erik Anderson (Corporate Broking)
FTI Consulting, LLP	+44 (0) 20 3727 1000
Matt Dixon / Jamille Smith / Tom Blundell

 

 

About LoopUp Group plc

 

LoopUp (LSE AIM: LOOP) is a cloud platform for premium specialist communications, focusing on capabilities that complement foundational unified communications platforms, such as Microsoft Teams. The Group's flagship Cloud Telephony solution for Microsoft Teams enables enterprise customers to eliminate disparate on-premises phone systems and multiple telecommunications service providers, and consolidate their global telecommunications into a single cloud implementation. LoopUp's global IP backbone interconnects with 18 carefully selected regional carrier partners and the Group has market-leading coverage as a licensed telecommunications service provider. The Group is listed on the AIM market of the London Stock Exchange (LOOP) and is headquartered in London, with offices in the US, Spain, Germany, Hong Kong, Barbados and Australia. For further information, please visit: www.loopup.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTKELFFFFLFFBX

Close

×

RNS Number : 0057S

Deepverge PLC

11 November 2021

 

11 November 2021

DeepVerge PLC

 

("DeepVerge" or "the Company")

 

U.S. launch of Skin Trust Club at Beauty Connect in Los Angeles

 

B2C and B2B offerings unveiled

 

 

 

DeepVerge (LSE:DVRG.L), announces that the Skin Trust Club is live in the U.S. following its launch to industry at Beauty Connect, Los Angeles on 4-5 November 2021. The U.S. launch is part of a five-event roadshow to industry that is unveiling what Skin Trust Club is all about and illustrating its power as a new game changing service in the skin health business.

 

At industry events in London (Pure Beauty) on 28 October 2021, Los Angeles (Beauty Connect) 4-5 November 2021, Boston (Microbiome Connect) 17-18 November 2021,  Amsterdam (Microbiome Connect) 7-8 December 2021 and San Francisco (Personalised Beauty Summit) 30-31 March 2021, scientists from DeepVerge are briefing industry on the facets of the Skin Trust Club service:

 

· A science based personalised skincare service for consumers;

· A clinical trial for industry where microbiome samples are collected before, during and after trials to see granular effects;

· A personalised shopping experience where Skin Trust Club customers only see products relevant to their skin with science and AI based recommendations for skin health routines; and

· A databank of thousands of skin sample data with AI models constantly learning about different types of skin and the effects of lifestyle, medications, environment and skin products and ingredients on that skin.

 

With Skin Trust Club laboratories in York, UK, and Delaware, US, and a new laboratory in Cork, Ireland, coming online to serve the EU market, Skin Trust Club is available in two major markets – UK and US – and will also be available in selected EU countries by the end of this year.

 

Gerard Brandon, CEO of DeepVerge, commented:

"With the service now available across all platforms and an in-house back office system that has been tested at scale, we are now showing the power of the service as a B2C offering but also as a game changing B2B offering. The industry is realising that with Skin Trust Club, the Holy Grail of personalised beauty and skincare is here. Our partner programme is seeing leading brands sign up to sell the service as part of their product/service offerings, to use the service as part of their clinical trials and finally to see the impact the largest skin microbiome database in the world can have on moving skin science and their research forward.

 

"With Skin Trust Club, we've had moments where servers were overloaded with demand and where partners are imploring us to move into their core markets quicker than we initially planned. Thankfully by making the strategic decision to build everything in-house – sequencing, software, AI – thereby controlling the normalisation of the service, we have the flexibility to move fast to scale. With exciting events this year and a roadmap that includes replicating the service for scalp, hands, legs and feet, both industry and consumers know that the future of skincare is based on deep science.

 

"As a business, we are also seeing the full impact of the synergies within our business where our Labskin and Data/AI companies are working hand-in-hand to create a new service that the Board believes will have a profound effect on the skin health industry worldwide."

 

 

 

For further information please contact:

 

DeepVerge plc	Gerard Brandon, CEO	+44 (0) 7340 055 648
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	+44 (0) 113 370 8974
Turner Pope Investments (TPI) Limited (Broker)	Andy Thacker/James Pope	+44 (0) 20 3657 0050

 

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins. Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin microbiome for most of the top 20 global cosmetic company clients and remotely detect and identify in real-time, dangerous pathogens in wastewater treatment plants, drinking water, rivers, lakes and reservoirs.

 

Labskin (Life Science Division)

Labskin have been pioneering the development of a laboratory grown human skin platform for more than 13 years and is the only commercially available lab-grown full thickness human skin model that naturally mimic the skin's microbiome. With top 20 global consumer health and skincare clients, thousands of industry tests, the good and bad bacteria that naturally exists on human skin is present on Labskin when testing skin care, cosmetics, health care, drug delivery or wound care products. The Labskin test platform and protocols help clients maintain an optimum real-world environment, when testing their new ingredients and existing skincare products, that shows the positive or negative impact on skin's natural microflora.

 

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRADKKBBOBDDKDD

Close

×

RNS Number : 5682R

Light Science Tech. Holdings PLC

08 November 2021

 

 

Light Science Technologies Holdings plc

("LSTH" or the "Company")

 

Zenith and Rentokil Contracts Update

 

Light Science Technologies Holdings plc (AIM: LST), the controlled environment agriculture ("CEA") technology and contract electronics manufacturing ("CEM") group, announces the start of its contract with Zenith Nurseries Ltd ("Zenith Nurseries") with a total potential value of up to £13.84 million*.

 

· Commencement of contract potentially worth up to £13.84 million*

· New cloche product to extend routes to market

· New orders from existing client in CEM division underpinning strong forward order book

 

As disclosed in the Company's Admission Document, the project involves a consortium (Light Science Technologies Ltd, Zenith Nurseries and Morrish Engineering Limited) developing a cloche lighting and sensor technology system.

 

This innovative product seeks to bring lighting and sensor technology to the controlled environment technology market for growers in polytunnel and glasshouse environments. Furthermore, the solution is intended to extend the use of the Company's nurturGROW Sensor to new market applications, such as agriculture fields. The cloche lighting and sensor technology system is expected to be the first retrofittable, all-in-one lighting-sensing-automation rig providing year-round harvests for the grower across multiple plant varieties.

 

With an initial potential UK market of 4,000 industrial growers, producing over 300 types of field-scale and protected vegetable and salad crops, and tree and berry fruits, the solution will aim to improve productivity by increasing yields. It will look to help growers by providing a possible solution to labour shortages and reduce the need for import substitution by extending the harvest window.

 

* subject, inter alia, to certain milestones and conditions as more fully described in the Company's announcement on 15 October 2021 .

 

Contract Electronics Manufacturing Update

 

UK Circuits and Electronics Ltd has received new orders from Rentokil Initial plc totalling c. £580,900 which are expected to be delivered through the first half of FY 2022, underlying our confidence in the prospects for this division.

 

The forward order book for UK Circuits and Electronics Ltd currently stands at approximately £5 million.

 

 

Simon Deacon, CEO of Light Science Technologies Holdings plc, commented: " The development of the LED grow lighting cloche/rig solution is an exciting progression in our product portfolio. We are delighted to be working with growers in the development of tailored supplementary hybrid lighting (LED and natural light) system providing targeted, actionable data insights of the nine cardinals of plant life and soil health, based upon the data collected.

 

"We already have good levels of visibility across both our divisions which provides a solid platform for growth. Importantly, we have a growing number of routes to increased commercialisation and believe that we are well placed to scale up rapidly."

 

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon publication of this announcement, this information is now considered to be in the public domain.

 

For further information, please contact:

 

Light Science Technologies Holdings plc	www.lightsciencetechnologiesholdings.com
Simon Deacon, Chief Executive Officer Jim Snooks, Chief Financial Officer Andrew Hempsall, Chief Operating Officer	via Walbrook PR
Strand Hanson Limited (Nominated & Financial Adviser)	Tel: +44 (0) 20 7409 3494
James Harris / Ritchie Balmer / Rob Patrick
Turner Pope Investments (TPI) Ltd (Broker)	Tel: +44 (0) 20 3657 0050
James Pope / Andy Thacker
Walbrook PR Ltd (Media & Investor Relations)	Tel: +44 (0)20 7933 8780 or  [email protected]
Nick Rome / Paul McManus / Nicholas Johnson

 

About Light Science Technologies Holdings plc ( www.lightsciencetechnologiesholdings.com )

 

Light Science Technologies Holdings plc was incorporated in England and Wales on 13 January 2020 and is the holding company of the Group's contract electronics manufacturing ("CEM") division, UK Circuits and Electronics Solutions Limited, and its controlled environment agriculture ("CEA") division, Light Science Technologies Ltd.

 

UK Circuits was founded in 1997 and is a contract electronics manufacturer with strong revenue and cash generation. The Group's manufacturing facilities in Manchester, United Kingdom enable the Group to design, manufacture and test high-quality CEM products used in a broad range of sectors.

 

Light Science Technologies was founded in September 2019 and facilitates the Company's CEA operations. The Group's state-of-the-art laboratory facilities in Derby, United Kingdom, enable the Group to design, test and provide innovative CEA products and services.

 

The CEM focussed division of the Group, UK Circuits, designs, procures and manufactures high-quality CEM products, specialising in PCBs, for over 70 recurring customers, which are used in a range of sectors, including, audio, automotive, electronics, gas detection, lighting, and pest control. The UK Circuits design team works alongside customers with new and existing product designs to provide design and engineering support, including simulation, 3D modelling, and prototyping. UK Circuits' procurement offerings range from assembly of free issue components to full turnkey solutions, leveraging the experience of its dedicated supply chain team and relationships with reputable suppliers.

 

In addition to the Group's CEM capability, the Group's CEA division, offers integrated, cost-saving and sustainable CEA solutions to crop growers, with a focus on the indoor, vertical and medicinal farming markets, which is expected to be the major growth area for the Group going forwards in light of the market landscape and in view of competing offerings currently in the marketplace. Light Science Technologies' all-in-one CEA solution includes analysing customers' crop growing requirements to provide bespoke, low-energy products, which subsequently monitor the environment in order to maintain optimal growing conditions through the nine cardinals of plant life (namely air speed, carbon dioxide levels, humidity, light, oxygen, plant disease, soil, temperature and water pH levels) to maximise crop yields and minimise resource usage.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

UPDBQLFBFFLLFBE

Close

×

Neville Registrars is delighted to welcome Silverwood Brands PLC as the newest addition to its list of client companies.

Silverwood Brands is an investment vehicle focused on identifying investment opportunities of premium consumer brands in the food, organic food, wellness, lifestyle and leisure sectors.

Further information can be found on the Company's website: https://www.silverwoodbrands.com/

Close

×

Neville Registrars is delighted to welcome Kasei Holdings plc as the newest addition to its list of client companies.

Kasei Holdings is an investment company specialising in the digital asset ecosystem, enabling investment in all aspects of this market in the form of a simple listed security. 

Further information can be found on the Company's website: https://kaseiholdings.com/

Close

×

RNS Number : 9453Q

NetScientific PLC

01 November 2021

 

NetScientific plc

("NetScientific", the "Group" or the "Company")

 

PDS to License Novel Proteins for Flu Vaccine

 

PDS Biotech Announces Agreement with University of Georgia to License Novel Proteins for Versamune-based Universal Flu Vaccine

 

 

London, UK – 01 November 2021 – NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group,  announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), has announced an agreement to license COBRA (Computationally Optimized Broadly Reactive Antigen) antigens from the University of Georgia initially for use in the clinical development of its infectious disease immunotherapy pipeline, PDS0202, a universal flu vaccine candidate.

 

Designed by renowned influenza expert, Dr. Ted Ross at the University of Georgia, the novel COBRA antigens are to be used in combination with Versamune® for PDS0202 for the universal prevention of infection by multiple strains of influenza virus. The antigens were selected following successful pre-clinical development work completed under a contract from the National Institute of Allergy and Infectious Diseases (NIAID), Collaborative Influenza Vaccine Innovation Centers (CIVICs) program to progress PDS0202 development. PDS0202 leverages Versamune®'s ability to induce the immune system to generate high levels of flu-specific neutralizing antibodies, CD4 helper and CD8 killer T-cells, as well as long-acting memory T-cells to potentially provide broad and long-term protection against multiple influenza strains. Influenza is estimated to result in about 3 to 5 million cases of severe illness and about 290,000 to 650,000 respiratory deaths globally each year.

 

PDS Biotech CEO, Frank Bedu-Addo commented: "Our new agreement with the University of Georgia demonstrates the versatility and potential of our Versamune® platform and advances our infectious disease pipeline.

 

"There are four types of seasonal influenza viruses, and a universal flu vaccine would eliminate the need to manufacture a new seasonal flu vaccine each year by providing robust, long-lasting protection against multiple subtypes of flu. We believe this is the next step in the advancement of novel infectious disease vaccines to address the nearly one billion cases of influenza worldwide annually."

 

Ilian Iliev, CEO of NetScientific, commented: "This latest development further demonstrates the PDS team's ability to execute a sophisticated programme of clinical applications of the Versamune® platform, not only in cancer-immunotherapy, but also in infectious disease vaccines – a rapidly growing area of market significance"

NetScientific's interest in PDS amounts to c. 4.72 per cent.

 

The full text of the announcement from PDS Biotechnology is available online here: https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/113-2021-news/573-iotechnnouncesgreementwithniversityofeorgia20211101

 

For more information, please contact:

NetScientific	Via Walbrook PR
Ilian Iliev, CEO
WH Ireland (NOMAD, Financial Adviser and Broker)
Chris Fielding / Darshan Patel	+44 (0)20 7220 1666
Walbrook PR
Nick Rome/ Paul McManus/ Nicholas Johnson	07748 325 236, 07980 541 893 or 07884 664 686

 

About NetScientific

NetScientific plc (AIM: NSCI) is a holding company, that invests in, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies, which offer significant growth potential predominately in the UK and USA, as well as globally. 

 

With the acquisition of EMV Capital in August 2020, the Group doubled its portfolio from 8 to 17 companies, either through direct subsidiary, balance sheet investment or capital under advisory, varying from start-up private companies to publicly listed equities. 

 

NetScientific delivers shareholder returns through a proactive and hands-on management approach to their portfolio companies; identifying, investing in, and helping to build game-changing companies. The Group targets value inflection points and the release of value through partial or full exits from trade sales, public listings, or equity sales. The Company has a strong transatlantic and growing international presence, providing attractive expansion prospects. 

 

NSCI can deploy a capital-light investment structure; utilising the power of the PLC Brand, and the NetScientific balance sheet to anchor future investments and achieve a multiplier effect by attracting 3rd party investment for the portfolio companies. 

 

NetScientific is headquartered in London, United Kingdom, and was admitted to trading on AIM, a market operated by the London Stock Exchange, in 2013 (website:  netscientific.net ).

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRADKDBKQBDDNDK

Close

×

RNS Number : 0193Q

Biome Technologies PLC

25 October 2021

 

 

25 October 2021

 

Biome Technologies plc

("Biome", the "Group" or the "Company")

Update re biodegradable tree shelters

 

Biome's Bioplastics division ( www.biomebioplastics.com ) announces the commencement of large-scale UK-wide field testing and initial commercial sales by Suregreen of biodegradable tree shelters using the Biome's proprietary bioplastics materials. Extended field testing of approximately 40,000 shelters at more than 40 sites is being carried out in close collaboration with Suregreen, a leading UK-based manufacturer of tree shelters.

The biodegradable tree shelters are designed to provide the benefits of traditional shelters for five years but to biodegrade naturally and harmlessly over the subsequent two years, offering an environmentally sustainable solution that improves forestry yields. The natural decay of the shelters has been demonstrated through extensive accelerated weathering, biodegradation in the laboratory and initial field testing.

Having developed these tree shelters in association with Suregreen (supported by a development contract from Innovate UK as part of the Sustainable Innovation Fund (SBRI Phase 2)), Biome and Suregreen will now monitor the product's performance to confirm high sapling survival rates in forestry conditions over the next few years. Customers can now also purchase the shelters made out of Biome's biodegradable materials from Suregreen under the "Vigilis Bio" brand ( http://www.sure-green.com/vigilis-bio.html ).

These trials come at a time when the UK prepares to host the 2021 United Nations Climate Change Conference, in Glasgow, also known as COP26. Biome is signed-up to the United Nations' Race to Zero campaign, and this product demonstrates its support for the UK achieving net-zero carbon emissions by 2050.

Paul Mines, Biome Technologies' Chief Executive Officer, commented:

"Extensive field testing is the next step to commercialisation of the novel biodegradable tree shelter at scale. We're looking forward to validating our results over the coming years in a diverse range of climates by demonstrating how our biodegradable materials can protect saplings in the early years after planting and are confident that biodegradable tree shelters will play a meaningful role in sustainable forestry and the UK's net-zero ambitions."

 

Editor's notes:

Tree shelters protect young trees and bushes from predation by animals. They are a well-proven and economic route to limiting losses in the first five years of a tree's life. Traditionally made from oil-based and non-biodegradable plastics, the majority of such shelters are not collected and litter the environment with microplastics.

In the UK, around 45 million trees are planted each year, most of those using non-biodegradable tree shelters for protection, resulting in an estimated 2,500 tons per annum of persistent microplastics remaining in the natural environment after use.

Plans to significantly increase tree planting have been announced recently by the UK Government in the Net Zero Strategy to triple planting rates from 13,660 hectares across the UK in 2020 to 30,000 hectares each year by the end of this Parliament.

More details on the scientific approach to this project and its future path to fuller commercialisation can be found in a short explanatory video commissioned by the Company that can be viewed here: https://youtu.be/gd6nsuYXopw .

Suregreen has also released a video https://youtu.be/-77nbgeuUhU and explanatory webpage www.sure-green.com/vigilis-bio.html supporting the launch of the tree shelters.

 

-Ends-

 

For further information please contact: Biome Technologies plc

Paul Mines, Chief Executive Officer

Donna Simpson-Strange, Company Secretary

[email protected]

Tel: +44 (0) 2380 867 100

www.biometechnologiesplc.com

 

Allenby Capital

David Hart/Alex Brearley (Nominated Adviser)

Kelly Gardiner (Sales and Corporate Broking)

Tel: +44 (0) 20 3328 5656

www.allenbycapital.com

 

About Biome

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

The Group comprises two divisions, Biome Bioplastics Limited and Stanelco RF Technologies Limited.

Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The company's mission is to produce bioplastics that challenge the dominance of oil-based polymers.

Stanelco RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets.

 

www.biometechnologiesplc.com

www.biomebioplastics.com   and  www.thinkbioplastic.com  

www.stanelcorftechnologies.com

   

About Suregreen

Suregreen is a leading manufacturer and e-commerce supplier of products for the forestry, fencing and landscaping markets. Situated in Essex, it offers nationwide delivery using a range of its own craned vehicles and national transport providers. Further details can be found at www.sure-green.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCBRBDGBDDDGBD

Close